Sourcebio International PLC
LSE:SBI
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
Market Cap | EV/EBITDA | ||||
---|---|---|---|---|---|
UK |
Sourcebio International PLC
LSE:SBI
|
85.3m GBP | 4.3 | ||
US |
C
|
Cigna Group
XMUN:CGN
|
92.4B EUR | 9.9 | |
US |
Cigna Corp
NYSE:CI
|
99.1B USD | 9.8 | ||
US |
CVS Health Corp
NYSE:CVS
|
70.7B USD | 8.7 | ||
US |
Laboratory Corporation of America Holdings
NYSE:LH
|
17.8B USD | 12.4 | ||
DE |
Fresenius SE & Co KGaA
XETRA:FRE
|
16.1B EUR | 10.2 | ||
US |
Quest Diagnostics Inc
NYSE:DGX
|
15.6B USD | 11 | ||
DE |
F
|
Fresenius Medical Care AG & Co KGaA
XETRA:FME
|
11.9B EUR | 7 | |
DE |
Fresenius Medical Care AG
XMUN:FME
|
11.8B EUR | 7 | ||
US |
DaVita Inc
NYSE:DVA
|
12B USD | 8.3 | ||
US |
Oak Street Health Inc
NYSE:OSH
|
9.5B USD | -23.3 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.